Intellia Therapeutics, Inc.

What they do

Intellia develops one-time, systemically administered CRISPR gene editing product candidates using lipid nanoparticle delivery. Its lead programs are lonvoguran ziclumeran (lonvo-z) for hereditary angioedema and nexiguran ziclumeran (nex-z) for ATTR amyloidosis, both in Phase 3 trials. The company also collaborates with Regeneron and other partners on earlier-stage programs.

Revenue drivers

• Collaboration revenue — Revenue primarily comes from collaboration agreements, including with Regeneron, rather than product sales. Annual revenue was $67.7 million in 2025.
• Research and development services — Revenue includes fees for R&D services performed under collaboration and license agreements, contributing to quarterly revenue that varied from $7.7 million to $23.0 million in recent quarters.
• License and option payments — Upfront and milestone payments from partnerships provide additional revenue, though no specific amounts are disclosed in the filings provided.

Recent performance

For Q2 2026 (ended June 30, 2026), revenue was $7.7 million, down from $23.0 million in Q4 2025 and $15.0 million in Q1 2026. The company reported positive Phase 3 HAELO results for lonvo-z, with an 87% reduction in HAE attacks versus placebo and a mean monthly attack rate of 0.26. Net loss for 2025 was $-412.7 million, improved from $-519.0 million in 2024. Cash and equivalents were $106.1 million at quarter-end, though total cash, cash equivalents and marketable securities were approximately $628 million.

Strategy

Intellia is focused on completing Phase 3 trials for lonvo-z and nex-z, with lonvo-z BLA submission expected in H2 2026 and U.S. launch planned for H1 2027. The company is building a U.S.-focused commercial and medical affairs field force to support a potential launch. It also continues to expand its pipeline through internal research and collaborations, including with Regeneron. Management expects cash to fund operations at least into 2028.

Risks

• Regulatory and approval risk — FDA acceptance of the lonvo-z BLA and subsequent approval are not guaranteed; delays or rejections would impact the planned 2027 launch.
• Clinical trial execution risk — Enrollment in nex-z Phase 3 trials was reinitiated in Q2 2026; failure to complete MAGNITUDE-2 enrollment or positive results would impair the program.
• Financing risk — Despite a recent capital raise, the company continues to generate operating losses and negative cash flow, requiring additional funding to sustain operations beyond 2028.
• Commercialization risk — As a first-in-class in vivo gene editing therapy, lonvo-z faces uncertain market acceptance, pricing and reimbursement, and the company has no commercial infrastructure experience.

Outlook

Management anticipates FDA acceptance of the lonvo-z BLA in the second half of 2026 and a U.S. launch in the first half of 2027. Enrollment in the nex-z Phase 3 MAGNITUDE-2 trial is expected to be completed in the second half of 2026. The company expects to fund operations at least into 2028 using its current cash position.